IDXG Stock — Interpace Biosciences, Inc.: Metrics

Market overview

2 metrics

Share price

$3.25

Market cap

$42.19M

Price action

19 metrics

Price change (1W)

—

Price change (30D)

—

Price change (3M)

—

Price change (6M)

—

Price change (YTD)

—

Price change (1Y)

—

Trailing year

Price change (5Y)

—

52-week high

—

52-week low

—

Change from 52-week high

—

Change from 52-week low

—

Annualized volatility

—

Beta

—

RSI (14D)

—

Price vs SMA 50

—

Price vs SMA 200

—

Avg volume (3M)

—

Relative volume

—

Average dollar volume

—

Company

3 metrics

Sector

Healthcare

Industry

Diagnostics & Research

Shares outstanding

5.54M

Valuation

12 metrics

P / E (TTM)

0.6

Trailing earnings · reciprocal yield 155.4%

PEG ratio

0.0

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

1.2×

reciprocal yield 85.7%

P / book

1.8

reciprocal yield 55.1%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

9.5

reciprocal yield 10.6%

Earnings yield

57.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2021-01-20

Profitability

9 metrics

Gross margin

63.7%

Operating margin

11.5%

Trailing 12 months

Net margin

67.6%

Gross profit (TTM)

$23.04M

Operating profit (TTM)

$4.17M

Net income (TTM)

$24.45M

Trailing 12 months

Diluted EPS (TTM)

$5.05

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-26.97

Growth

11 metrics

Revenue growth YoY

-1.1%

Year over year

Net income growth YoY

+266.7%

Revenue (TTM)

$36.14M

Trailing 12 months

EPS growth YoY

+122.5%

Shares change YoY

+526.6%

Year over year · more shares

Revenue CAGR (3Y)

+89.6%

Revenue CAGR (5Y)

+3.6%

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

105.2%

Return on assets

70.8%

Debt / equity

—

Current ratio

2.2

EBITDA (TTM)

$4.64M

Free cash flow (TTM)

—

Quick ratio

2.0

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$2.69M

Total assets

$34.55M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

$4.46M

Capital expenditures (TTM)

—

R&D (TTM)

$594,000

SG&A (TTM)

—

Stock compensation (TTM)

$19,000

R&D / revenue

1.6%

Stock compensation / revenue

0.1%

Ownership (13F)

3 metrics

13F filers

—

13F filer change QoQ

—

Institutional ownership

—

Short interest

3 metrics

Short interest

—

Latest settlement

Days to cover

—

Short-squeeze score

—

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

IDXG · Interpace Biosciences, Inc.

IDXG metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search